TNFSF13B and relapsing-remitting multiple sclerosis: In a cross-sectional study of 78 patients with relapsing-remitting MS (RRMS), serum BAFF levels increased 3-fold during the first month after treatment and remained significantly elevated compared to baseline levels at all subsequent time points up to 12 months.